Benhealth Pharmaceutical

Benhealth Biopharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative immunotherapies for cancer and autoimmune diseases. The company leverages a proprietary platform to develop a diverse pipeline of next-generation immune checkpoint inhibitors, including monoclonal and bispecific antibodies. Their lead programs focus on targeting established and emerging pathways such as PD-1/PD-L1, CTLA-4, and TIGIT to overcome resistance in solid tumors. Benhealth aims to provide high-quality, affordable biopharmaceuticals to patients globally through internal R&D and strategic collaborations.